Recent advances in siRNA delivery mediated by lipid-based nanoparticles

Yonezawa, Sei; Koide, Hiroyuki; Asai, Tomohiro

doi:10.1016/j.addr.2020.07.022

Cited by 258 publications

(165 citation statements)

References 210 publications

(230 reference statements)

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“… 1 Oligonucleotides, such as small interfering RNAs (siRNAs), are promising drug modality for a variety of diseases. 2 As a 21–23 bp double-stranded RNA molecule, siRNAs could induce a sequence-specific posttranscriptional gene silencing by targeting complementary nucleotide sequence. 3 However, there are still many obstacles for application of siRNAs in clinical.…”

Section: Introductionmentioning

confidence: 99%

Preparation Optimization of Bovine Serum Albumin Nanoparticles and Its Application for siRNA Delivery

Wang¹,

Chen²,

Yang³

et al. 2021

DDDT

View full text Add to dashboard Cite

Background siRNA brings hope for cancer therapy. However, there are many obstacles for application of siRNA in clinical. Because of the excellent biocompatibility, non-toxicity and non-immunogenicity of bovine serum albumin (BSA), BSA-based nanoparticles have been widely designed as a drug carrier system. Methods The optimal formula for BSA NPs preparation was investigated by central composite design response surface methodology (CCD-RSM), BSA-based survivin-siRNA delivery system (BSA NPs/siRNA) was characterized by dynamic light scattering, atomic force microscope, transmission electron microscope and Bradford method. The in vitro anti-tumor effect and mechanism of BSA NPs were investigated by confocal microscopic imaging, MTT assay, RT-qPCR and ELISA analysis. Moreover, the anti-tumor effect, distribution and biosafety of BSA NPs were studied in vivo. Results The optimal formula for BSA NPs was settled to be 20 mg/mL for BSA concentration, 9 for pH value, 136% for crosslinking degree and 1.6 mL/min for speed of ethanol addition. BSA NPs/siRNA could remain stable at 4°C for 4 weeks and protect siRNA from degradation by RNase A. Besides, BSA NPs/siRNA could maintain a sustained release of siRNA and promote the uptake of siRNA significantly. The survivin-mRNA level and the survivin-protein level were decreased by 55% ± 1.6% and 54% ± 1.6% separately. The in vivo tumor inhibition results suggested that the tumor inhibition rate of BSA NPs/siRNA-treated group was 54% ± 12% and was similar with that of DOX-treated group (57% ± 9.2%, P > 0.05). The biosafety results confirmed that BSA NPs/siRNA could not induce significant damages to the main organs and blood in vivo. Conclusion These results demonstrated that CCD-RSM was an effective tool for preparation analysis, and the BSA NPs/siRNA was a promising system for siRNA-based gene therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation Optimization of Bovine Serum Albumin Nanoparticles and Its Application for siRNA Delivery

Wang¹,

Chen²,

Yang³

et al. 2021

DDDT

View full text Add to dashboard Cite

show abstract

“…For example, these naked tools are easily degraded and exhibit low delivery in the cellular environment. However, some investigations suggest that the conjugation of these tools with NSs could improve their therapeutic action [ 94 , 95 , 154 , 159 , 160 , 161 , 162 ].…”

Section: Nanotechnology Approaches For Hiv/aids Treatmentmentioning

confidence: 99%

Nanosystems Applied to HIV Infection: Prevention and Treatments

Macchione

Bedoya

Figueroa

et al. 2020

IJMS

View full text Add to dashboard Cite

Sexually-transmitted infections (STIs) are a global health concern worldwide as they cause acute diseases, infertility, and significant mortality. Among the bacterial, viral, and parasitic pathogens that can be sexually transmitted, human immunodeficiency virus (HIV) has caused one of the most important pandemic diseases, which is acquired immune deficiency syndrome (AIDS). 32.7 million people have died from AIDS-related illnesses since the start of the epidemic. Moreover, in 2019, 38 million people were living with HIV worldwide. The need to deal with this viral infection becomes more obvious, because it represents not only a problem for public health, but also a substantial economic problem. In this context, it is necessary to focus efforts on developing methods for prevention, detection and treatment of HIV infections that significantly reduce the number of newly infected people and provide a better quality of life for patients. For several decades, biomedical research has been developed allowing quick solutions through the contribution of effective tools. One of them is the use of polymers as vehicles, drug carrier agents, or as macromolecular prodrugs. Moreover, nanosystems (NSs) play an especially important role in the diagnosis, prevention, and therapy against HIV infection. The purpose of this work is to review recent research into diverse NSs as potential candidates for prevention and treatment of HIV infection. Firstly, this review highlights the advantages of using nanosized structures for these medical applications. Furthermore, we provide an overview of different types of NSs used for preventing or combating HIV infection. Then, we briefly evaluate the most recent developments associated with prevention and treatment alternatives. Additionally, the implications of using different NSs are also addressed.

show abstract

“…The small interfering RNAs (siRNAs), are a promising approach for gene therapy, however their intracellular administration remains difficult. To date, a great variety of delivery system for siRNAs has been investigated such as lipids, polymers, aptamers and cell penetrating peptides (CPPs) [ 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 ]. In this regard, CPPs appear as a new class of transporters, which increase intracellular uptake of biologically active molecules including siRNAs [ 45 ] ( Figure 2 ).…”

Section: Benefit Of Cpps Used As Vehicles In Oligonucleotides Delimentioning

confidence: 99%

Cell Penetrating Peptides Used in Delivery of Therapeutic Oligonucleotides Targeting Hepatitis B Virus

et al. 2020

View full text Add to dashboard Cite

Peptide Nucleic Acid (PNAs) and small noncoding RNAs including small interfering RNAs (siRNAs) represent a new class of oligonucleotides considered as an alternative therapeutic strategy in the chronic hepatitis B treatment. Indeed, chronic hepatitis B virus (HBV) infection remains a major public health problem worldwide, despite the availability of an effective prophylactic vaccine. Current therapeutic approaches approved for chronic HBV treatment are pegylated-interferon alpha (IFN)-α and nucleos(t)ide analogues (NAs). Both therapies do not completely eradicate viral infection and promote severe side effects. In this context, the development of new effective treatments is imperative. This review focuses on antiviral activity of both PNAs and siRNAs targeting hepatitis B virus. Thus, we briefly present our results on the ability of PNAs to decrease hepadnaviral replication in duck hepatitis B virus (DHBV) model. Interestingly, other oligonucleotides as siRNAs could significantly inhibit HBV antigen expression in transient replicative cell culture. Because the application of these oligonucleotides as new antiviral drugs has been hampered by their poor intracellular bioavailability, we also discuss the benefits of their coupling to different molecules such as the cell penetrating peptides (CPPs), which were used as vehicles to deliver therapeutic agents into the cells.

show abstract

Recent advances in siRNA delivery mediated by lipid-based nanoparticles

Cited by 258 publications

References 210 publications

Preparation Optimization of Bovine Serum Albumin Nanoparticles and Its Application for siRNA Delivery

Preparation Optimization of Bovine Serum Albumin Nanoparticles and Its Application for siRNA Delivery

Nanosystems Applied to HIV Infection: Prevention and Treatments

Cell Penetrating Peptides Used in Delivery of Therapeutic Oligonucleotides Targeting Hepatitis B Virus

Contact Info

Product

Resources

About